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The association between the use of oral con-
traceptives with an increased thromboembolic
risk has first been described in the early 1960s
when case reports were published on pul-
monary embolism (1) and ischemic stroke (2)
m women using these drugs. The magnitude of
the thromboembolic risk was thought to be re-
lated to the estrogen content; however, recent
reports have shown relative risks of 4 to 6 for
deep vein thrombosis with recent low-estro-
gen-containing anti-contraceptives, which is
not substantially different from older reports.
Furthermore, hormonal replacement therapy,
which has an extremely low estrogen content
compared to anticonceptives, still increases
the risk for venous thromboembolism by 2.1-
to 3.6-fold. Several recent studies have shown
that it is not just the estrogen component of an-
ticonceptives that is responsible for the risk of
venous thrombosis since preparations contain-
ing a third-generation progestin (desogestrel,
gestodene) lead to a twofold higher risk than
products containing a second-generation prog-
estin (mostly levonergestrel).
Studies published in the 1970s showed an
increased risk of thrombotic stroke and an in-
creased risk of acute myocardial infarction in
current users of oral contraceptive agents. Re-
cently published case-control studies no
longer find an increased risk of ischemic
stroke with the current use of low-dose anti-
conceptives (<50 μg estrogen), with the ex-
ception of hypertensive or smoking women.
Current users of postmenopausal hormone
Substitution have a relative risk of 0.50 of
coronary heart disease äs compared to
nonusers. The association of progestin to es-
trogen does not seem to attenuate the cardio-




ORAL CONTRACEPTIVES AND RISK
OF VENOUS THROMBOEMBOLISM
The association of the use of oral contra-
ceptives and an increased risk of venous
thromboembolic disease has been well estab-
lished in a series of epidemiologic studies
(3-5). Several studies have suggested a dose-
response relation between the estrogen com-
ponent of oral contraceptives and the magni-
tude of the thrombotic risk (6-8), which
extends from 50 to 30 μg of estrogen (9). In
the latter study the relative risk of venous
thromboembolism in users of oral contracep-
tives containing >50 μg of estrogen äs com-
pared to those taking <50 μg of estrogen was
1.7. In the WHO Collaborative Study of Car-
diovascular Disease and Steroid Hormone
Contraception (10), the odds ratios for venous
thromboembolic disease tended to be lower
when first- and second-generation progesta-
gens were used in combination with low (<50
μ§ estrogen) rather than higher estrogen
doses; in the Leiden thrombophilia study (11)
the risk conferred by oral contraceptives con-
taining 30 or 50 μg ethinylestradiol was the
same. The risk reduction that has occurred by
lowering the estrogen content of oral contra-
ceptives, if any, has certainly not been a dra-
matic one. The early case-control studies in
the 1960s reported relative risks for idiopathic
deep vein thrombosis ranging from 4 to 8
(12-14), whereas in the most recent studies
oral contraceptives still are found to be asso-
ciated with a four- to sixfold increased risk
(10,15,16). No other lifestyle or environmen-
tal risk factor influenced in a consistent way
the risk for venous thromboembolism with
the exception of body mass index, which was
a weak independent risk factor; the odds ra-
tios associated with venous thromboem-
bolism were higher among those with a body
mass index (BMI) above 25 kg/m2 than
among those with smaller BMIs (10).
Several studies pubhshed in 1995-1996
camc \ \ i t h an unexpected result : The nsk for
\ e n o u s thromboembolism is not only i n f l u -
enced b\ estrogen content but also h\ t \ p e of
progestagen used. So-called th i rd-genera t ion
oral contraceptives, containing desogestrel (
gestodene äs a progestagen, were associate
with a twofold higher risk for venous thron
boembolism than those containing a seconc
generation progestagen such äs le\
onorgestrel. The published studies were
subanalysis of women exposed to third-genei
ation oral contraceptive pills of the WH<
Collaborative Study of Cardiovascular Oh
ease and Steroid Hormone Contraceptio
(17); a case-control study of current users c
the oral contraceptive pill from the Britis
general practice research database (18); a re
analysis of the Leiden thrombophilia stud
(11); and a multinational case-control stud
(15). All studies indicated a doubling of th
adjusted odds ratio for venous thromboerr
bolism in patients taking third- rather tha
second- generation oral contraceptive pills.
Venous thromboembolism is quite rare i
the age group of women taking oral contra
ceptives. Most recent studies report inci
dences of around l per 10 000 women yean·
this figure increases to 4 per 10,000 wome
years in women using second-generation con
traceptives and around 6 to 10 per 10,00·
with the use of third-generation contracep
tives.
Low-dose oral contraceptives containin;
third-generation progestagens seem to be les
androgenic and have less impact on carbohy
drate and lipoprotein metabolism than othe
low-dose preparations (19); recent review
have concluded that these third-generatioi
preparations do not differ from earlier low
dose contraceptives in their impact on hemo
static variables. The changes in hemostatu
Parameters, at least for those that can be mea
sured, in women using oral contraceptives an
minor and generally remain within the norma
ränge. Furthermore, it has been suggested tha
the use of oral contraceptives induces change;
in the procoagulant and anticoagulant path
ways that may counterbalance each othei
(19-21). Recently it was shown, using ;
method measuring endogenous thrombin po-
tential of plasma. that the sensitivity to acti-
\ a t ed protem C (APC) was decreased ir
\\omen using oral contraceptives, indepen-
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dent of the kind of contraceptive used.
Women who used third-generation oral con-
traceptives were less sensitive to APC than
\somen using second-generation oral contra-
ceptives and became comparable to female
carriers of the factor V Leiden mutation
\\ hich causes inherited APC resistance and is
the most common cause of inherited throm-
bophilia (22). Joining their data on impaired
\PC sensitivity with epidemiologic data,
these authors suggest that the increased inci-
dence of venous thrombosis in women using
oral contraceptives, especially in those using
third-generation contraceptives, might be QK-
plained by acquired APC resistance. The e\-
act molecular mechanism behind the throm-
bogenic potential of oral contraceptives
remains to be elucidated (23).
The increased risk of venous thromboem-
bolism appears to be related to current use of
anticonceptives. In the WHO study (10) the
increased odds ratios were fully realized
within 4 months of starting oral contracep-
tives and had resolved within 3 months of
stopping. These findings are in keeping with
previous publications (4,24,25) and suggest
that disturbance of coagulation balances in-
duced by the anticonceptive are involved.




Until recently the risk of venous throm-
boembolism associated with postmenopausal
hormone replacement therapy was thought to
be probably nonexistent or at most very small;
however, few epidemiologic studies had as-
sessed the relation between postmenopausal
hormones and thrombotic disease and most of
them were too small to provide reliable esti-
mates (26-28). The risk of venous throm-
boembolism associated with oral anticoncep-
tives is to a large extent attributable to its
estrogen content and the hemostatic alter-
ations induced by postmenopausal replace-
ment therapy on hemostatic parameters have
been shown to be similar though less pro-
nounced than with oral contraceptives; the
paradoxical absence of increased venous
thromboembolic risk was explained by the
significantly lower estrogen content of post-
menopausal hormones and different type of
estrogen used. The results of three large stud-
ies studying the effect of postmenopausal hor-
mone replacement therapy on venous throm-
boembolism (29,30) or pulmonary embolism
(31) resolved the apparent paradox. In each of
these studies a twofold to fourfold increased
risk of venous thromboembolism was shown
with estrogen-only äs well äs with combined
estrogen-progestagen hormone replacement
therapy. The risk seems to be higher shortly
after the Start of therapy (29,30). In these
studies, women suffering from thromboem-
bolic disease who had other risk factors for
thrombosis, such äs recent trauma or surgery,
previous thromboembolism, cardiac disease,
diabetes, or cancer, were excluded. Further re-
search will be needed to establish the safety of
postmenopausal hormone therapy when other
risk factors for venous thromboembolism, in-
cluding obesity, recent surgery, immobiliza-





Hereditary defects in the natural anticoag-
ulant pathways, the antithrombin pathway
(including antithrombin deficiency), and the
protein C pathway (including deficiencies of
protein C and protein S and resistance to ac-
tivated protein C) predispose patients to the
development of venous thromboembolism.
Data on the thrombotic risk of women with
antithrombin (AT), protein C (PC), and pro-
tein S (PS) deficiencies taking oral contra-
ceptives are anecdotal due to the low preva-
lence of these defects. In a retrospective
study of 96 women with proven deficiencies
of either AT, PC, or PS, Pabinger et al. (32)
found that the probability for thrombosis
was significantly higher in AT deficient pa-
tients taking oral contraceptives äs compared
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to AT deficient patients not taking contra-
ceptives. In patients with protein C or pro-
tein S deficiency there was no clear differ-
ence between users or non-users of oral
contraceptives. Due to the higher prevalence
of resistance to activated protein C, gener-
ally explained by the factor V Leiden muta-
tion, more data are available concerning the
risk of venous thrombosis associated with
the use of oral contraceptives in this group.
Data from the Leiden Thrombophilia Study
(16) showed a fourfold increased risk for
thrombosis among users of oral contracep-
tives, an eightfold increased risk of thrombo-
sis among carriers of the factor V Leiden
mutation compared with noncarriers, and a
>30-fold increased risk for women who both
were carriers of the mutation and used oral
contraceptives. In this study the incidence of
first venous thrombosis in women aged 15 to
49 years not using oral contraceptives was
0.8 per 10,000 person-years in noncarriers of
factor V Leiden and 5.7 per 10,000 person-
years in carriers of the mutation; in users of
contraceptives the incidences rose to 3.0 per
10,000 person-years and 28.5 per 10,000
person-years, respectively. The absolute in-
crease in thrombosis risk due to oral contra-
ceptives is much larger in women who carry
the factor V Leiden mutation than in women
who do not. In a study of 29 patients ho-
mozygous for the factor V Leiden mutation
oral contraceptives were found to enhance
the risk of clinical manifestation of venous
thrombosis at a young age (33). The factor V
Leiden mutation was also shown to enhance
the risk of deep vein thrombosis associated
with oral contraceptives containing a third-
generation progestagen (l 1). The risk of fac-
tor V Leiden carriers using a desogestrel
containing anticonceptive is almost 50-fold
increased äs compared with noncarrier
nonusers.
Although an enhancement of the risk of ve-
nous thromboembolism associated with the
use of postmenopausal hormone replacement
therapy by these hcreditary thrombophil ic
condit ions might be ant ic ipated no data on
th i s subject are currentlv available.
ORAL CONTRACEPTIVES AND RISK
OF STROKE AND MYOCARDIAL
INFARCTION
The issue of an increased risk of stroke as-
sociated with the use of oral contraceptives
has been addressed in several, mostly retro-
spective studies (34,35). Relative risks among
users of contraceptives in these studies were
found between 3.7 and 4.8. Since most of
these studies were conducted during a period
when pills with a high estrogen and progesta-
gen content were widely used, several recent
studies were undertaken to address the ques-
tion of whether recent contraceptives with low
hormone contents still carry an increased risk
of stroke. In a Danish retrospective case-con-
trol study o f women aged 15 to 44 years who
had suffered a thromboembolic attack without
known predisposing factor, a crude odds ratio
of 3 was found (36). After correcting for con-
founders such äs age, smoking, and years of
schooling, pills containing 50 μg estrogen
were associated with an odds ratio for cere-
bral thromboembolic attack of 2.9 and those
containing 30 to 40 μg estrogen with an odds
ratio of 1.8. Progesterone-only pills did not
increase the risk of a cerebral thromboem-
bolic attack. Cigarette smoking increased the
risk of cerebral thromboembolic attacks by
50% independent of oral contraceptive use or
age. In the report of the WHO Collaborative
Study of Cardiovascular Disease and Steroid
Hormone Contraception (37) the overall odds
ratio of ischemic stroke in women aged 20 to
44 taking combined oral contraceptives was
2.99 in Europe and 2.93 in non-European
countries. Odds ratios associated with contra-
ceptives containing <50 μg of estrogen were
l .53 and substantially higher (5.30) for prepa-
rations containing >50 μg of estrogen. In this
study odds ratios were lower in younger
women and those who did not smoke, but
among current users of oral contraceptives
with a history of hypertension the odds ratio
was 10.7.
The same study group (38) reported no in-
creased risk of hemorrhagic stroke associated
\vi th contraceptives in women younger t l u n
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1 5 years Odds ratios were >2 for women
older than 35 years and >3 for those who also
smoked cigarettes Current users of oral con-
traceptives with a history of hypertension
ι \v ith the exception of pregnancy-related hy-
pertension) had a 10- to 15-fold increased risk
of hemorrhagic stroke äs compared with
nonusers without history of hypertension
Another recent study of the risk of stroke m
users of low-dose oral contraceptives (con-
tammg <50 μg of estrogen) did not show an
increased risk for ischemic stroke or for hem-
orrhagic stroke (39) A positive mteraction
between the current use of oral contraceptives
ind smokmg was found with respect to the
risk of hemorrhagic stroke Considenng the
\\ idth of their confidence mterval and the re-
siilts of the Danish study (36), Pettiti and col-
leagues conclude that the true relative risk of
stroke among users of oral contraceptives, äs
Lompared with nonusers, is <2 5 Smce the
absolute incidence of ischemic stroke m
\oung healthy women is small (5 4/100,000
\vomen-years accordmg to Pettiti), the ab-
solute mcrease in incidence of stroke m cur-
rent users of oral contraceptives will also be
Shortly after their introduction oral contra-
teptives were associated with acute myocar-
dial mfarction m a case report (40) This as-
sociation was thereafter confirmed m several
case-control and cohort studies (41-44)
More recent studies conducted m the 1990s
and dealmg mainly with newer contracep-
tives, which have low estrogen content and are
used by younger women who do not have
other nsk factors for cardiovascular disease,
could no longer demonstrate mcreases m nsk
of acute myocardial mfarction associated with
oral contraceptives (45-47) In the WHO Col-
laborative Study of Cardiovascular Disease
and Steroid Hormone Contraception, 368
\vomen aged 20 to 44 with a defmite or possi-
ble acute myocardial mfarction who were ad-
mitted to hospital were studied (48) Women
trom Afnca, Asia, Europe, and Latin America
uere included The overall odds ratio for
acute myocardial mfarction was 5 0 m Europe
and 4 8 in the developmg countnes However,
odds ratios associated with the use of oral
contraceptives were not increased in women
without other cardiovascular nsk factors such
äs smokmg or hypertension The estimated
excess nsk in such women in the European
centers was about 3 per 106 Among oral con-
traceptive users who smoke 10 or more ciga-
rettes per day, the odds ratios were >20 and
the degree of excess risk associated with oral
contraceptives is substantial only in older
women who smoke (about 400 per 106
women-years) Whereas a risk reduction for
cardiovascular events associaied with third-
generation äs compared with second-genera-
tion progestagens has been anticipated based
on less androgenic activity with an advanta-
geous effect on hpid profile and possibly car-
bohydrate mechanism (49), it has yet to be
clanfied äs to whether the risk of artenal dis-
eases dunng treatment with the newer formu-
lations differs from that of the older prepara-
tions (50) Two studies have failed to show a
difference m the risk of ischemic stroke for
users of third-generation contraceptives com-
pared to second-generation contraceptives
(37,51) Initial results of an international
case-control study suggest a reduced risk of
myocardial mfarction associated with third-
generation oral contraceptives äs compared
with second-generation preparations, but are
based on a small number of cases (n = 6) and
controls (n = 34) (odds ratio of 0 45 with wide
confidence mtervals) (52) This study con-
firms that the greatest nsk for health comes
from smokmg while taking the pill, rather
than from the type of pill being used, young
women smokers who use the pill are 10 times
more hkely to suffer myocardial mfarction
than users who don't smoke (53)
While consistent reports show an increased
nsk of venous thrombotic disease with third-
generation oral contraceptives, it is not yet
clear if and how they differ from second-gen-
eration contraceptives m their nsk on myocar-
dial mfarction If the latter will prove to be the
case, decision analysis models will have to be
set up that take into account the differences in
age-dependent baseline nsks for venous and
artenal thrombotic disease Such model may
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lead to preferential use of second-generation
contraceptives in younger women and third-
generation contraceptives in older women (54).
As for the risk of venous thromboem-
bolism, the increased risk for myocardial in-
farction is associated with current use of anti-
conceptives. No increase in odds ratio was
apparent with increasing duration of use
among current users, and odds ratios were not
increased in women who had stopped using
oral contraceptives, even after long exposure
(48). This again suggests that the effects are
due to disturbances in coagulation rather than





In a meta-analysis of many observational
studies (55) an Overall risk reduction of ap-
proximately 36% was found when estrogen
users were compared with those who had
never used estrogen. Furthermore, the data
suggest that most of this apparent protection
is among the current hormone users who had
a relative risk of 0.49. An even greater benefit
was found in women with coronary heart dis-
ease: A summary relative risk from angio-
graphic studies comparing women with oc-
clusion to those without was 0.39. In several
studies a reduction of all-cause mortality was
documented (56,57). In a recent study of mor-
tality associated with long-term post-
menopausal hormone therapy (58), the age-
adjusted relative risk of death from any cause
was 0.54 in estrogen users and was largely
due to reductions in coronary heart disease.
However, currently much debate i s ongoing
whether the protective effect seen in these
studies may be due, at least in part, to selec-
tion bias. Different authors observed that
women who use estrogen replacement therapy
are healthier and have a better cardiovascular
risk profile prior to estrogen replacement
therapv than \\omen \\ho do not takc hor-
mones ( 5 9 - 6 1 ) . Houcxcr. adjustment for
known cardiac risk factors in many o
large studies did not have a major impa«
the results (56,57,62).
The proposed mechanisms of cardiov;
lar protection are a reduction of low-de
lipoprotein, an increase of high-de
lipoprotein, and an increase of triglyce
that results in an overall improvement c
lipid profile (63). Estrogen replacement
apy has been found to reduce lipoprote
levels toward premenopausal values (64
to impede the oxidation of low-de
lipoprotein (LDL) cholesterol (65). Th
fects of estrogen replacement therapy o
coagulation System are inconsistent: it k
fibrinogen and plasminogen activatoi
hibitor but it also lowers antithrombin
protein C, which have an anticoagulant
tion (66). Estrogen replacement therapy
favorably influences endothelium fun
and vascular tone (67,68).
Currently, to avoid abnormal endom
proliferation and endometrial cancer, a
estin is associated with the estrogen. )
ever, progestins tend to raise LDL and
HOL levels (69) and to oppose the effei
estrogen on vascular tone (70). In three r
studies an almost identical reduction ir
diovascular risk was found when wome
ceiving estrogens plus progestin were
pared with women receiving estrogen
(71-73). In addition, the decrease of
minogen activator inhibitor I induced b
trogen or estrogen combined with me
yprogesterone acetate was not different
recent randomized crossover study (74).
CONCLUSION
Currently used combined oral antico
tives with low estrogen content still ho
increased risk of venous thromboembc
The risk of thromboembolism is not con
to the estrogen component but is also d
dent on the type of progesterone.
Postmenopausal hormone replaa
therapy carries a t\vo- to fourtbkl risk t
nous thromboemboIiMTi.
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Inhented thrombophiha and oral contra-
».eptives have a synergistic effect on the nsk
ot venous thromboembohsm
The nsk of stroke and myocardial infarc-
uon associated with the use of oral contracep-
tives is very small in young women without
other cardiovascular nsk factors When other
nsk factors such äs smokmg or hypertension
ire present, the risk mcreases substantially
Postmenopausal hormone replacement
iherapy reduces cardiovascular risk regardless
\\ hether estrogen only or combmed estrogen-
progestm treatment are used However the
nagnitude of this reduction still is matter of
Jebate, many authors argue that selection to-
\\ards healthier women with less preexisting
^irdiovascular risk factors for treatment with
^trogen replacement may bias the results
REFERENCES
1 Jordan WM Pulmonary embolism Lancet 1961 2
1146-1147
2 Lorentz IT Panetal lesion and "Enovid" Bt Med J
1962,2 1191
Stadel BV Oral contraceptives and cardiovascular disease
(first of two parts) N Eng/ J Med 1981,305 612-618
-l Vessey MP Female hormones and vascular disease—an
epidemiological overview Br J Fant Plann 1980
(suppl) 1-12
^ Sartwell PE, Stolley PD Oral contraceptives and vascu-
lar disease Epidemiol Re\ 1982,495-109
Ί Inman WH, Vessey MP, Westerholm B, Engelund A
Thromboembolic disease and the steroidal content of
oral contraceptives A report to the Committee on
Safety of Drugs Br Med J 1970,2 203-209
" Stolley PD, Tonascia JA, Tockman MS, Sartwell PE,
Rutledge AH Jacobs MP Thrombosis with low-estro-
gen oral contraceptives Am J Epidemiol 1975 102
197-208
*> Bottmger LE, Bowan G, Eklund G Oral contraceptives
and thromboembolic disease effects of lowenng oe-
strogen content Lancet 1980,1 1097-1101
' Gerstman BB, Piper JM, Tomita DK, Ferguson WJ,
Stadel BV, Lundm FE Oral contraceptive estrogen dose
and the nsk of deep venous thromboembolic disease
4m J Epidemiol 1991,133 32-37
Ί Venous thromboembolic disease and combmed oral
contraceptives Results of international multicentre
case-control study World Health Orgamzation Collabo-
rative Study of Cardiovascular Disease and Steroid Hor-
mone Contraception Lancet 1995,346 1575-1582
i Bloemenkamp KW, Rosendaal FR, Heimerhorst FM,
Buller HR Vandenbroucke JP Enhancement by tactor
V Leiden mutation of nsk of deep-vem thrombosis as-
sociated with oral contraceptives containmg a third-
generation progestagen Lancet 1995 346 1593-1596
- Inman WH Vessey MP Imestigation of deaths from
pulmonary, coronary, and cerebral thrombosis and em-
bolism m women of child-beanng age Br Med J 1968,
2 193-199
13 Vessey MP, Doll R Investigation of relation between
use of oral contraceptives and thromboembolic disease
BrMedJ\96S,2 199-205
14 Sartwell PE, Masi AT, Arthes FG, Greene GR, Smith
HE Thromboembohsm and oral contraceptives an epi-
demiologic case-control study Am J Epidemiol 1969,
90 365-380
15 Spitzer WO, Lewis MA, Hememann LA, Thorogood M,
MacRae KD Third generation oral contraceptives and
nsk of venous thromboembolic disorders an interna-
tional case-control study Transnational Research Group
on Oral Contraceptives and the Health of Young
Women B? Med J 1996 312 83-88
16 Vandenbroucke JP, Koster T, Briet E, Reitsma PH,
Bertina RM, Rosendaal FR Increased nsk of venous
thrombosis in oral-contraceptive users who are carners
of factor V Leiden mutation Lancet 1994,344
1453-1457
17 Effect of different progestagens in low oestrogen oral
contraceptives on venous thromboembolic disease
World Health Orgamzation Collaborative Study of Car-
diovascular Disease and Steroid Hormone Contracep-
tion Lancet 1995,346 1582-1588
18 Jick H, Jick SS, Gurewich V, Myers MW Vasilakis C
Risk of idiopathic cardiovascular death and nonfatal ve-
nous thromboembohsm in women usmg oral contracep-
tives with diffenng progestagen components Lancet
1995 346 1589-1593
19 Speroff L, DeCherney A Evaiuation of a new genera-
tion of oral contraceptives The Advisory Board for the
New Progestms Obstet Gynecol 1993,81 1034-1047
20 Stubblefield PG The effects on hemostasis of oral con-
traceptives containmg desogestrel Am J Obstet Gvnecol
1993 168 1047-1052
21 Newton JR Classification and companson of oral con-
traceptives containmg new generation progestogens
Hum Repiod Update 1995 l 231-263
22 Rosmg J, Tans G, Nicolae GAF, et al Oral contracep-
tives and venous thrombosis different sensitivities to
activated protem C in women usmg second- and third-
generation oral contraceptives Bi J Haematol 1997,97
233-238
23 Vandenbroucke JP, Rosendaal FR End of the line for
"third-generation-ριΙΓ controversy11 Lancet 1997,349
1113-1114
24 Helmnch SP, Rosenberg L, Kaufman DW, Strom B
Shapiro S Venous thromboembolism m relation to oral
contraceptive use Obstet Gynecol 1987,69 91-95
25 Stadel BV Oral contraceptives and cardiovascular dis-
ease (second of two parts) N Eng/ J Med 1981,305
672-677
26 Surgically confirmed gallbladder disease, venous
thromboembohsm, and breast tumors in relation to
postmenopausal estrogen therapy A report from the
Boston Collaborative Drug Surveillance Program,
Boston Umversity Medical Center N Engt J Med 1974,
290 15-19
27 Pettiti DB Wmgerd J, Pellegnn F Ramcharan S Risk of
vascular disease m women smokmg oral contracep-
tives, noncontraceptive estrogens and other factors
JAMA 1979242 1150-1154
28 Devor M Barrett Connor E Renvall M, Feigal D Jr
718 CHAPTER 42
Ramsdell J Estrogen replacement therapy and the nsk 46
of venous thrombosis Am J Med 1992,92 275-282
29 Daly E, Vessey M P, Hawkms MM, Carson JL, Gough P,
Marsh S Risk of venous thromboembolism in users of 47
hormone replacement therapy Lancet 1996,348
977-980
30 Jick H, Derby LE, Myers MW, Vasüakis C, Newton
KM Risk of hospital admission for idiopathic venous 48
thromboembolism among users of postmenopausal oe-
strogens Lancet 1996,348 981-983
31 Grodstem F, Stampfer MJ, Goldhaber SZ, et al
Prospective study of exogenous hormones and nsk of
pulmonary embohsm m women Lancet 1996,348 49
983-987
32 Pabmger l, Schneider B Thrombotic nsk of women
with hereditary antithrombm III-, protem C- and protem 50
S-deficiency takmg oral contraceptive medication The
GTH Study Group on Natural Inhibitors Thromb 51
Haemost 1994,71 548-552
33 Rmtelen C, Mannhalter C, Ireland H, et al Oral contra-
ceptives enhance the nsk of clmical mamfestation of ve- 52
nous thrombosis at a young age in females homozygous
for factor V Leiden Bi J Haematol 1996,93 487-490
34 Thorogood M, Mann J, Murphy M, Vessey M Fatal
stroke and use of oral contraceptives fmdmgs from a
case-control study Am J Epidemiol 1992 136 35-45
35 Mettinger KL, Soderstrom CE, Neiman J Stroke before 53
55 years of age at Karolmska Hospital 1973-77 A study
of 399 well-defmed cases Risk mdicators and etiologi- 54
cal considerations Aaa Neuroi Scand 1984,70
415-^22
36 Lidegaard O Oral contraception and nsk of a cerebral
thromboembolic attack results of a case-control study 55
B> MedJ 1993,306 956-963
37 Ischaemic stroke and combmed oral contraceptives re-
sults of an international, multicentre, case-control study
WHO Collaborative Study of Cardiovascular Disease 56
and Steroid Hormone Contraception Lancet 1996,
348 498-505
38 WHO Collaborative Study of Cardiovascular Disease
and Steroid Hormone Contraception Haemorrhagic 57
stroke, overall stroke nsk, and combmed oral contra-
ceptives results of an international, multicentre, case-
control study Lancet 1996,348 505-510 58
39 Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry
C, Ziel HK Stroke m users of low-dose oral contracep-
tives Λ EnglJ Med 1996,335 8-15
40 Boyce J, Fawcett JW, Nall EWP Coronary thrombosis 59
andConovid Lancet 1963,1 111
41 Mann JI, Thorogood M, Waters WE, Powell C Oral
contraceptives and myocardial mfarction m young
women a further report Bi Med J 1975,3 631-632 60
42 Jick H Oman B Rothman KJ Oral contraceptives and
nonfatal myocardial mfarction JAMA 1978,239
1403-1406 61
43 Shapiro S Slone D Rosenberg L, Kaufman DW, Stolley
PD Miettmen OS Oral-contraceptive use in relation to
myocardial mfarction Lancet 1979 l 743-747
44 Slone D Shapiro S Kaufman DW Rosenberg L, Miet- 62
tinen OS Stollcv PD Risk of mvocardial mfarction m
relition to uirrent and distontmucd use ot oral t_ontra-
n.pti\e-, \ / H«/ / l/u/ l'M ich 420 424
4^ I horojood M \ l i n n l M u i p h s M \e-^c\ M N onl M
L o n t i in.pu\i. u». M i l l I X M K I it<_d u u h m mui-iM.d n^k
ot t ml i m o i j i d i i l I n t u i t i o n ' Report öl J L .IM. lomrol
-tud\ HI Ι Ο / ^ u t (nmiiiiil 14 ') l 9s 124^ !>'
Rosenberg L, Palmer JR, Lesko SM, Shapiro S Oral
contraceptive use and the nsk of myocardial mfarction
Am J Epidemie! 1990 131 1009-1016
Sidney S, Petitti DB, Quesenberry CP Jr, Klatsky AL,
Ziel HK, Wolf S Myocardial mfarction in users of
low-dose oral contraceptives Obstet Gvnecol 1996,88
939-944
Acute myocardial mfarction and combmed oral contra-
ceptives results of an international multicentre case-
control study WHO Collaborative Study of Cardiovas-
cular Disease and Steroid Hormone Contraception
Lancet 1997,349 1202-1209
Wilde MI, Balfour JA Gestodene A review of its phar
macology, efficacy and tolerability m combmed contra
ceptive preparations Drwgi 1995,50364-395
Kühl H Comparative pharmacology of newer progesto-
gens Drugs 1996,51 188-215
Lidegaard O, Mtlsom I Oral contraceptives and throm
botic diseases impact of new epidemiological studies
Contraception 1996,53 135-139
Lewis MA, Spitzer WO, Heinemann LA, MacRae KD
Bruppacher R, Thorogood M Third generation oral
contraceptives and nsk of myocardial mfarction an in-
ternational case-control study Transnational Research
Group on Oral Contraceptives and the Health of Young
Women BrMedJ 1996,312 88-90
McPherson K Third generation oral contraception and
venous thromboembolism BrMedJ 1996,312 68-69
Schwnngl PJ, Shelton J Modeled estimates of myocar-
dial mfarction and venous thromboembolic disease m
users of second and third generation oral contraceptiveb
Contraception 1997,55 125-129
Grodstem F, Stampfer M The epidemiology of coro-
nary heart disease and estrogen replacement in post-
menopausal women Prag Cardiovasc Dis 1995,38
199-210
Bush TL, Barrett Connor E, Cowan LD, et al Cardiovas-
cular mortahty and noncontraceptive use of estrogen m
women results from the Lipid Research Clmics Program
Follow-up Study Circulation 1987,75 1102-1109
Henderson BE, Paganmi Hill A, ROSS RK Decrcased
mortahty m users of estrogen replacement therapy Aiili
Intern Med 1991 151 75-78
Ettmger B, Fnedman GD, Bush T, Quesenberry CP Jr
Reduced mortahty associated with long-term post-
menopausal estrogen therapy Obstet Gynecol 1996 87
6-12
Posthuma WF, Westendorp RG, Vandenbroucke JP Car-
dioprotective effect of hormone replacement therapy m
postmenopausal women is the evidence biased' Br
Med J 1994,308 1268-1269
Sturgeon SR, Schairer C, Bnnton LA, Pearson T,
Hoover RN Evidence of a healthy estrogen user sur-
vivor effect Epidemiology 1995,6227-231
Matthews KA, Kuller LH, Wmg RR, Meilahn FN,
Plantinga P Pnor to use of estrogen replacement ther-
apy, are users healthier than nonusers9 Am J Epidemiol
1996 143971-978
Stampfer MJ, Colditz GA, Willett WC, et al Po-,t-
menopausal estrogen therapy and cardiovasculir dis
ease Ten-\ear follow-up from the nurses health ••md\
\ r/ii,'/ / Uti/ 1991 ̂  -"56 762
\\aUhB\\ Sduft l Rosner B Greenber« I R i \ m U \
Siiks l M f fiet.K ot postmenopausal ^trogen KJ KI.
ηκηι on the LOiKenl ia t ions and nietabolisni ot p l i ^ n i i
lipoprotcm-, \ / H I ; / / \Ud 1991 12> 1196 1204
VENOUSAND ARTERIAL THROMBOEMBOLISM AND HORMONE THERAPY 719
JR, Lesko SM, Shapiro s . ,
the nsk of myocardul ml u\
131 1009-1016
Quesenberry CP Jr k lakk
socardial infarction m UM
eptives Obstet G\ m-i nl \ v n
irction and combmed o r i l L ι
n international mul t iccnin ^
ollaborative Studv of C inh
ueroid Hormone Contr.it L p
: 1209
Gestodene \ reviev. öl ι ι^ ρ
d tolerabihty m combinul ι
Dings 1995,50 364 39*
pharmacology of neuer pro_
1S8-215
l Oral contraceptives am) i l i
t of new epidemiologn. il -iu
3 Π5-139
\ O Heinemann LA M u. R u \
ogood M "Ihird gener i t i o n
^k of myocardial mfaruion
ι öl study Transnational Ri.*
n_eptives and the Heal th öl Ί
196 312 88-90
generation oral contran.pt ι
msm Bi Med J 1996 11 2 < -
n J Modeled estimates öl in
enous thromboemboln. diM
lurd generation oral u in t ru i i
•̂  125-129
er M The epidemiolog\ · ι
ind estrogen replacemem in
Prag Carduna\c Dn l '
inor E, Cowan LD et al t ird
loncontraceptive use öl estn
the Lipid Research Clinii^ l't
uilation 1987,75 1102 I H N
mini Hill A, ROSS RK IXu
estrogen replacement ther ip\
l 75-78
n GD, Bush T, Quesenberr\ ι '
associated with long t u n i
n therapy Obstet G\nci<>/ l ' '
endorp RG. VandenbroiKkL H 1 '
ot hormone replacement th>·
imen is the evidente hi i -
dS-1269
nrer C, Bnnton L \ IV »-
IKC of a healthy estrog<-n u-
>noht>\ 1995.6227 2 ^ 1
i l l e r LH \ V i n g RR ^l^ 1"
o use of estrogen replu.uu.
h i e r than nonusers' ('" ' /
du/ GA. \ \ i l l e t t \ \ C u '
ui therapv and tardio^ i - ^ '
n\ up from the ΠΙΙΓΜ.·· ΙΊ- "
>:<; 7^6 762
Rosner B tjreenberg l K ι ·
> l postmenopausal esiro^tii
ntrations and meuboli-w ι
' / Mni 1991 -!2^ 1196 Γ'1·
Sacks FM, McPherson R, Walsh BW Effect of post-
menopausal estrogen replacement on plasma Lp(a)
hpoprotem concentrations Arch inrein Med 1994 154
1106-1110
Sacks MN, Rader DJ, Cannon RO Oestrogen and inhi- 70
bition of oxidation of low-density hpoprotems m post-
menopausal women Lancet 1994,343 269-270
Nabulsi AA, Folsom AR, White A, et al Association of 71
hormone-replacement therapy with vanous cardiovas-
cular nsk factors m postmenopausal women The Ath-
erosclerosis Risk in Commumties Study Investigators
V Engt J Med 1993,328 1069-1075 72
Herrington DM, Braden GA, Will iams JK, Morgan TM
Endothehal-dependent coronary vasomotor responsive-
ness in postmenopausal women with and without estro-
gen replacement therapy Am J Caidiol 1994,73 73
951-952
Reis SE, Gloth ST, Blumenthal RS, et al Ethmyl estra-
diol acutely attenuates abnormal coronary vasomotor
responses to acetylcholme m postmenopausal women 74
Ciiculation 1994,89 52-60
Miller VT, Muesmg RA, LaRosa JC, Stoy DB Phill ips
EA, Stillman RJ Effects of conjugated equine estrogen
with and without three different progestogens on
hpoprotems, high-density hpoprotem subfractions, and
apolipoprotem A-I Obstet Gvnecol 1991,77 235-240
Sarrel PM Blood F/OH Treatmenl of the Post-
menopausal Woman—Basic and Clinical Aspects New
York Raven Press, 1994,251-252
Falkeborn M, Persson I, Adami HO, et al The nsk of
acute myocardial mfarction after oestrogen and oestro-
gen-progestogen replacement Bi J Obstet Gynaecol
1992,99821-828
Psaty BM, Heckbert SR, Atkms D, et al The nsk of my-
ocardial mfarction associated with the combmed use of
estrogens and progestms in postmenopausal women
4tch Intern Med 1994 154 1333-1339
Grodstem F, Stampfer. MJ, Manson JE, et al Post-
menopausal estrogen and progestm use and the nsk of
cardiovascular disease N Engl J Med 1996,335
453-461
Kon Kon K, Mmcemoyer R, Bui MN, et al Effects of
hormone-replacement therapy on fibnnolysis in post-
menopausal women N Engl J Med 1997,336 683-690
